Loading clinical trials...
Loading clinical trials...
An Open-Label Titration Followed by a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Tolerability, and Safety of Oxymorphone Extended Release Tablets in Opioid-Naïve Patients With Chronic Low Back Pain
Conditions
Interventions
Oxymorphone Extended Release
Locations
33
United States
Southern Drug Research
Hueytown, Alabama, United States
Phoenix Center for Clinical Research
Phoenix, Arizona, United States
Express Care Clinical Research
Colorado Springs, Colorado, United States
New England Research
Bridgeport, Connecticut, United States
Glasgow Family Practice
Newark, Delaware, United States
Radiant Research
Daytona Beach, Florida, United States
Start Date
November 1, 2004
Completion Date
July 1, 2005
Last Updated
January 2, 2024
NCT07538427
NCT04587791
NCT04880096
NCT05885061
NCT05492825
NCT07317271
Lead Sponsor
Endo Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions